GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

InterMune Achieves $10M Milestone from Roche

  • InterMune received $10-million upon completion of a large-scale synthesis of the active pharmaceutical ingredient in Roche’s hepatitis C virus (HCV) drug candidate. ITMN-191 is currently in a Phase Ia trial.

    This milestone is part of the companies' collaboration to develop and commercialize novel protease inhibitors for the treatment of HCV. 

    "InterMune has successfully executed key steps in the manufacture of a sophisticated protease inhibitor molecule and transferred the materials to Roche for future studies," says Lawrence M. Blatt, Ph.D., CSO of InterMune.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?